Your browser doesn't support javascript.
loading
Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance : An Analysis From a Population-Based Screening Study.
Sverrisdottir, Ingigerdur; Thorsteinsdottir, Sigrun; Rognvaldsson, Sæmundur; Aspelund, Thor; Vidarsson, Brynjar; Onundarson, Pall Torfi; Agnarsson, Bjarni A; Sigurdardottir, Margret; Thorsteinsdóttir, Ingunn; Sveinsdottir, Signy Vala; Palmason, Robert; Olafsson, Isleifur; Sigurdsson, Fridbjorn; Thordardóttir, Asdis Rosa; Eythorsson, Elias; Jonsson, Asbjorn; Palsson, Runolfur; Indridason, Olafur Skuli; Gislason, Gauti Kjartan; Olafsson, Andri; Sigurdsson, Jon; Steingrímsdóttir, Hlif; Einarsson Long, Thorir; Hultcrantz, Malin; Durie, Brian G M; Harding, Stephen; Landgren, Ola; Kristinsson, Sigurdur Yngvi; Love, Thorvardur Jon.
Affiliation
  • Sverrisdottir I; University of Iceland, Reykjavik, Iceland, and Sahlgrenska University Hospital, Gothenburg, Sweden (I.S.).
  • Thorsteinsdottir S; University of Iceland, Reykjavik, Iceland, and Rigshospitalet, Copenhagen, Denmark (S.T.).
  • Rognvaldsson S; University of Iceland and Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (S.R., R.Palmason, S.Y.K., T.J.L.).
  • Aspelund T; University of Iceland, Reykjavik, Iceland (T.A., A.R.T., G.K.G., A.O., J.S.).
  • Vidarsson B; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Onundarson PT; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Agnarsson BA; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Sigurdardottir M; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Thorsteinsdóttir I; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Sveinsdottir SV; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Palmason R; University of Iceland and Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland, and Skåne University Hospital, Lund, Sweden (R.Palsson).
  • Olafsson I; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Sigurdsson F; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Thordardóttir AR; University of Iceland, Reykjavik, Iceland (T.A., A.R.T., G.K.G., A.O., J.S.).
  • Eythorsson E; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Jonsson A; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Palsson R; University of Iceland and Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (S.R., R.Palmason, S.Y.K., T.J.L.).
  • Indridason OS; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Gislason GK; University of Iceland, Reykjavik, Iceland (T.A., A.R.T., G.K.G., A.O., J.S.).
  • Olafsson A; University of Iceland, Reykjavik, Iceland (T.A., A.R.T., G.K.G., A.O., J.S.).
  • Sigurdsson J; University of Iceland, Reykjavik, Iceland (T.A., A.R.T., G.K.G., A.O., J.S.).
  • Steingrímsdóttir H; Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (B.V., P.T.O., B.A.A., M.S., I.T., S.V.S., I.O., F.S., E.E., A.J., O.S.I., H.S.).
  • Einarsson Long T; University of Iceland, Reykjavik, Iceland, and Skåne University Hospital, Lund, Sweden (T.E.L.).
  • Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York (M.H.).
  • Durie BGM; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, California (B.G.M.D.).
  • Harding S; Binding Site Group, Birmingham, United Kingdom (S.H.).
  • Landgren O; Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida (O.L.).
  • Kristinsson SY; University of Iceland and Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (S.R., R.Palmason, S.Y.K., T.J.L.).
  • Love TJ; University of Iceland and Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland (S.R., R.Palmason, S.Y.K., T.J.L.).
Ann Intern Med ; 177(6): 711-718, 2024 Jun.
Article de En | MEDLINE | ID: mdl-38768457
ABSTRACT

BACKGROUND:

Monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. In previous registry-based, retrospective studies, autoimmune diseases have been associated with MGUS. However, these studies were not based on a screened population and are therefore prone to ascertainment bias.

OBJECTIVE:

To examine whether MGUS is associated with autoimmune diseases.

DESIGN:

A cross-sectional study within iStopMM (Iceland Screens, Treats, or Prevents MM), a prospective, population-based screening study of MGUS.

SETTING:

Icelandic population of adults aged 40 years or older. PATIENTS 75 422 persons screened for MGUS. MEASUREMENTS Poisson regression for prevalence ratios (PRs) of MGUS among persons with or without an autoimmune disease, adjusted for age and sex.

RESULTS:

A total of 10 818 participants had an autoimmune disorder, of whom 599 had MGUS (61 with a prior clinical diagnosis and 538 diagnosed at study screening or evaluation). A diagnosis of an autoimmune disease was not associated with MGUS (PR, 1.05 [95% CI, 0.97 to 1.15]). However, autoimmune disease diagnoses were associated with a prior clinical diagnosis of MGUS (PR, 2.11 [CI, 1.64 to 2.70]).

LIMITATION:

Registry data were used to gather information on autoimmune diseases, and the homogeneity of the Icelandic population may limit the generalizability of these results.

CONCLUSION:

The study did not find an association between autoimmune disease and MGUS in a systematically screened population. Previous studies not done in systematically screened populations have likely been subject to ascertainment bias. The findings indicate that recommendations to routinely screen patients with autoimmune disease for MGUS may not be warranted. PRIMARY FUNDING SOURCE The International Myeloma Foundation and the European Research Council.
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies auto-immunes / Gammapathie monoclonale de signification indéterminée / Dépistage de masse Limites: Adult / Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Ann Intern Med Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies auto-immunes / Gammapathie monoclonale de signification indéterminée / Dépistage de masse Limites: Adult / Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Ann Intern Med Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique